Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome

Diagnostic Microbiology and Infectious Disease
Polydoros TofasGeorge L Daikos

Abstract

Our aims were to identify factors associated with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) in patients with hematological malignancies and evaluate the outcome of the affected patients. Consecutive patients with hematological malignancies who developed PA BSI were identified. Subsequently, two case-control studies were performed to evaluate the risk factors (i) for PA BSI and (ii) for carbapenem resistant (CR) PA BSI. Patients' outcome was evaluated at 28 days after the onset of bacteraemia. A total of 64 patients with PA BSI (45 caused by CS and 19 by CR organisms) and 128 without PA BSI were enrolled. Patients with rapidly fatal disease, steroid use, neutropenia or prior surgery were more likely to develop PA BSI, whereas patients with previous hospitalization and prior use of fluoroquinolones were more likely to develop CR PA BSI. The 28-day mortality rate was 35.9%. Severity of sepsis was the only independent predictor of adverse outcome.

Citations

Jun 27, 2018·ESMO Open·Matthias Gerhard VossenFlorian Thalhammer
Jul 20, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gemma Martinez-NadalCarolina Garcia-Vidal
Apr 13, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Theodoros KarampatakisEmmanuel Roilides
Jan 11, 2019·Antimicrobial Resistance and Infection Control·Di ZhangYalin Dong
Oct 13, 2020·Frontiers in Oncology·Matt S ZinterJeffery J Auletta
Dec 29, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yuanqi ZhaoSizhou Feng
Jul 12, 2019·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D ViasusC Garcia-Vidal
Apr 17, 2021·Infectious Diseases and Therapy·Carolina Garcia-VidalUNKNOWN ID-INNOVATION study group
Apr 26, 2021·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Gina K ThomsonKenneth S Thomson
May 15, 2021·European Journal of Haematology·Emilia ÅttmanReetta Huttunen
Sep 22, 2021·CA: a Cancer Journal for Clinicians·Amila K NanayakkaraDavid E Greenberg
Oct 14, 2021·International Journal of Antimicrobial Agents·Raúl RecioFernando Chaves

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.